Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NYXOAH TO RELEASE SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 5, 2026 MONT-SAINT-GUIBERT, BELGIUM  JULY 27, 2026, 10:05PM CET / 4:05PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 ON WEDNESDAY, AUGUST 5, 2026. COMPANY MANAGEMENT WILL HOST A CONFERENCE CALL TO DISCUSS FINANCIAL RESULTS THAT DAY BEGINNING AT 10:30PM CET / 4:30PM ET.

NYXOAH TO RELEASE SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 5, 2026

NYXOAH ANNOUNCES PRELIMINARY RESULTS FOR THE SECOND QUARTER OF 2026 CONTINUED U.S. LAUNCH MOMENTUM DRIVES SECOND QUARTER GLOBAL PRELIMINARY NET REVENUE OF 7.7 MILLION CMS PROPOSES 2027 OPPS AND ASC PAYMENT INCREASE OF 12% AND 15% RESPECTIVELY MONT-SAINT-GUIBERT, BELGIUM  JULY 7, 2026, 10:05 PM CET / 4:05 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY THAT DEVELOPS BREAKTHROUGH TREATMENT ALTERNATIVES FOR OBSTRUCTIVE SLEEP APNEA (OSA) THROUGH NEUROMODULATION, TODAY REPORTED CERTAIN PRELIMINARY UNAUDITED SECOND QUARTER 2026 FINANCIAL AND OPERATING RESULTS. SECOND QUARTER 2026  PRELIMINARY SALES AND MARKET METRICS FINANCIALS GLOBAL NET REVENUE IS EXPECTED TO BE APPROXIMATELY 7.7 MILLION IN THE SECOND QUARTER OF 2026, WHICH REFLECTS 21% SEQUENTIAL GROWTH OVER THE FIRST QUARTER OF 2026 U.S. NET REVENUE IS EXPECTED TO BE APPROXIMATELY 5.2 MILLION IN THE SECOND QUARTER OF 2026, WHICH REFLECTS 22% SEQUENTIAL GROWTH OVER THE FIRST QUARTER OF 2026 LEADING U.S. COMMERCIAL INDICATORS 55 NEW SURGEONS TRAINED IN Q2, BRINGING THE TOTAL TO 262 SURGEONS TRAINED 89 NEW ACCOUNTS ACTIVATED IN Q2, BRINGING THE TOTAL TO 180 ACTIVE HIGH-VOLUME ACCOUNTS 427 PATIENTS SUBMITTED UNDER PRIOR AUTHORIZATION ENTERING Q3 REIMBURSEMENT US CMS IS PROPOSING TO INCREASE HOSPITAL REIMBURSEMENT FOR THE GENIO PROCEDURE (C8011) FROM $31,526 TO $35,414, REPRESENTING AN INCREASE OF $3,888 (12%) CMS IS PROPOSING TO INCREASE ASC REIMBURSEMENT FROM $27,563 TO $31,722, AN INCREASE OF $4,159 (15%) LIQUIDITY $110 MILLION IN AGGREGATE FINANCING SECURED IN Q2 AS OF JUNE 30, 2026, CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS ARE EXPECTED TO BE APPROXIMATELY 97.8 MILLION "WE CLOSED Q2 WITH CLEAR U.S. MOMENTUM: THE SCALING OF OUR U.S. SALES FORCE ALLOWED US TO DOUBLE THE NUMBER OF ACTIVE ACCOUNTS TO 180 HIGH-VOLUME HGNS ACCOUNTS AND DELIVER A SECOND CONSECUTIVE QUARTER OF OVER 20% SEQUENTIAL U.S. REVENUE GROWTH.

NYXOAH ANNOUNCES PRELIMINARY RESULTS FOR THE SECOND QUARTER OF 2026

REGULATED INFORMATION INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MONT-SAINT-GUIBERT (BELGIUM), JUNE 30, 2026 , 10:30PMCET / 4:30PMET  IN ACCORDANCE WITH ARTICLE15 OF THE LAW OF MAY 2, 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS AND NASDAQ:NYXH) PUBLISHES THE BELOW INFORMATION FOLLOWING THE ISSUANCE OF 146,531 NEW SHARES ON JUNE 30, 2026 FOLLOWING THE EXERCISE OF SO-CALLED RESTRICTED SHARE UNITS. SHARE CAPITAL: EUR 7,075,152.31 TOTAL NUMBER OF SECURITIES CARRYING VOTING RIGHTS: 100,072,815 (ALL ORDINARY SHARES) TOTAL NUMBER OF VOTING RIGHTS (= DENOMINATOR): 100,072,815 (ALL RELATING TO ORDINARY SHARES) NUMBER OF RIGHTS TO SUBSCRIBE TO SECURITIES CARRYING VOTING RIGHTS NOT YET ISSUED: 3,731,884 (ALL GRANTED SUBSCRIPTION RIGHTS; THIS NUMBER EXCLUDES 36,125 SUBSCRIPTION RIGHTS THAT WERE ISSUED BUT NOT YET GRANTED) TOTAL NUMBER OF CONVERTIBLE BONDS: 225 CONVERTIBLE BONDS WITH A NOMINAL VALUE OF EUR83,000 PER BOND TOTAL NUMBER OF VOTING RIGHTS THAT CAN BE OBTAINED IN CASE OF CONVERSION OF ALL 225 CONVERTIBLE BONDS AT THE CURRENT (REVISED) CONVERSION PRICE OF EUR 1.48 PER SHARE: 12,618,243 (THIS NUMBER DOES NOT TAKE INTO ACCOUNT THE CONVERSION OF INTEREST) * * * CONTACT: NYXOAH JOHN LANDRY, CFOIR@NYXOAH.COM ATTACHMENT 2026 06 30 - PRESS RELEASE - NUMBER OF SHARES (ENG)

INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES

REGULATED INFORMATION PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS MONT-SAINT-GUIBERT (BELGIUM), JUNE 29, 2026 , 10:30 PM CET / 4:30 PM ET  IN ACCORDANCE WITH ARTICLE14 OF THE LAW OF MAY 2, 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) ANNOUNCES THAT IT RECEIVED TRANSPARENCY NOTIFICATIONS AS DETAILED BELOW. ORIN HIRCHMAN ON JUNE 24, 2026, NYXOAH RECEIVED A TRANSPARENCY NOTIFICATION FROM ORIN HIRCHMAN FOLLOWING AN ACQUISITION OF VOTING SECURITIES BY ENTITIES CONTROLLED BY ORIN HIRCHMAN.

PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS

NYXOAH TO HOST INVESTOR DAY IN NEW YORK ON JULY 8, 2026 LEADERSHIP TEAM AND BOARD WILL DISCUSS THE U.S. COMMERCIAL EXECUTION, GROWTH STRATEGY AND KEY PRIORITIES MONT-SAINT-GUIBERT, BELGIUM  JUNE 23, 2026, 10:05 PM CET / 4:05 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON DEVELOPING INNOVATIVE SOLUTIONS FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT IT WILL HOST AN INVESTOR AND ANALYST DAY ON WEDNESDAY, JULY 8, 2026, IN NEW YORK. THE EVENT WILL BE HELD AT THE OFFICES OF BANK OF AMERICA AND WILL RUN FROM 10:00 AM TO 12:30 PM ET (16:00 TO 18:30 CET).

NYXOAH TO HOST INVESTOR DAY IN NEW YORK ON JULY 8, 2026

REGULATED INFORMATION JUNE 19, 2026, 10:30PM CET / 4:30PM ET NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) RUE EDOUARD BELIN 12, 1435 MONT-SAINT-GUIBERT, BELGIUM(HEREINAFTER THE COMPANY) INVITATION TO ATTEND THE EXTRAORDINARY SHAREHOLDERS' MEETING OF THE COMPANY TO BE HELD ON JULY 9, 2026 THE BOARD OF DIRECTORS OF THE COMPANY IS PLEASED TO INVITE ITS SECURITIES HOLDERS TO ATTEND THE EXTRAORDINARY SHAREHOLDERS' MEETING OF THE COMPANY, TO BE HELD ON THURSDAY, JULY 9, 2026 AT 2:00P.M. CET AT THE COMPANY'S SEAT, OR AT SUCH OTHER PLACE AS WILL BE INDICATED PRIOR TO SUCH TIME.

INVITATION TO ATTEND THE EXTRAORDINARY SHAREHOLDERS' MEETING OF THE COMPANY TO BE HELD ON JULY 9, 2026

REGULATED INFORMATION PUBLICATION RELATING TO TRANSPARENCY NOTIFICATIONS MONT-SAINT-GUIBERT (BELGIUM), JUNE 17, 2026 , 10:30 PM CET / 4:30 PM ET  IN ACCORDANCE WITH ARTICLE14 OF THE LAW OF MAY 2, 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) ANNOUNCES THAT IT RECEIVED TRANSPARENCY NOTIFICATIONS AS DETAILED BELOW. ROBERT TAUB ON JUNE 16, 2026, NYXOAH RECEIVED A TRANSPARENCY NOTIFICATION FROM ROBERT TAUB FOLLOWING AN ACQUISITION OF VOTING SECURITIES BY ROBERT TAUB AND ROBELGA SRL (AN ENTITY CONTROLLED BY ROBERT TAUB).

NYXOAH RECEIVES $15 MILLION FROM THE EUROPEAN INVESTMENT BANK NON-DILUTIVE DEBT FUNDING COMPLEMENTS THE COMPANY'S JUNE EQUITY RAISE, BRINGING TOTAL CAPITAL RAISED TO $110 MILLION MONT-SAINT-GUIBERT, BELGIUM  JUNE 17, 2026, 10:05 PM CET / 4:05 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON DEVELOPING INNOVATIVE SOLUTIONS FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THAT IT HAS RECEIVED $15 MILLION (13.8 MILLION) IN PROCEEDS FROM THE SECOND TRANCHE OF ITS LOAN FACILITY WITH THE EUROPEAN INVESTMENT BANK (EIB). THE DRAWDOWN FOLLOWS THE RECENT CONFIRMATION THAT THE COMPANY HAD SATISFIED THE PREDEFINED CRITERIA REQUIRED TO ACCESS THIS TRANCHE.

NYXOAH RECEIVES $15 MILLION FROM THE EUROPEAN INVESTMENT BANK

REGULATED INFORMATION INFORMATION ON THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MONT-SAINT-GUIBERT (BELGIUM), JUNE 10, 2026 , 11:00PMCET / 5:00PMET  IN ACCORDANCE WITH ARTICLE15 OF THE LAW OF MAY 2, 2007 ON THE DISCLOSURE OF LARGE SHAREHOLDINGS, NYXOAH SA (EURONEXT BRUSSELS AND NASDAQ:NYXH) PUBLISHES THE BELOW INFORMATION FOLLOWING THE ISSUANCE OF 55,232,558 NEW SHARES IN CONNECTION WITH ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING IN THE UNITED STATES, WHICH INCLUDED SHARES SOLD IN A PRIVATE OFFERING TO CERTAIN QUALIFIED OR INSTITUTIONAL INVESTORS OUTSIDE THE UNITED STATES, INCLUDING WITHIN THE EUROPEAN UNION. SHARE CAPITAL: EUR 7,073,687.00 TOTAL NUMBER OF SECURITIES CARRYING VOTING RIGHTS: 99,926,284 (ALL ORDINARY SHARES) TOTAL NUMBER OF VOTING RIGHTS (= DENOMINATOR): 99,926,284 (ALL RELATING TO ORDINARY SHARES) NUMBER OF RIGHTS TO SUBSCRIBE TO SECURITIES CARRYING VOTING RIGHTS NOT YET ISSUED (ON MAY31, 2026): 3,322,832 (ALL GRANTED SUBSCRIPTION RIGHTS; THIS NUMBER EXCLUDES 462,677 SUBSCRIPTION RIGHTS THAT WERE ISSUED BUT NOT YET GRANTED) TOTAL NUMBER OF CONVERTIBLE BONDS: 225 CONVERTIBLE BONDS WITH A NOMINAL VALUE OF EUR83,000 PER BOND TOTAL NUMBER OF VOTING RIGHTS THAT CAN BE OBTAINED IN CASE OF CONVERSION OF ALL 225 CONVERTIBLE BONDS AT THE CURRENT (REVISED) CONVERSION PRICE OF EUR 1.48 PER SHARE: 12,618,243 (THIS NUMBER DOES NOT TAKE INTO ACCOUNT THE CONVERSION OF INTEREST) * * * CONTACT: NYXOAH JOHN LANDRY, CFOIR@NYXOAH.COM ATTACHMENT 2026 06 10 - PRESS RELEASE - NUMBER OF SHARES (ENG)

$110 MILLION IN AGGREGATE FINANCINGS TO ACCELERATE GENIO'S U.S. COMMERCIAL LAUNCH MONT-SAINT-GUIBERT, BELGIUM  JUNE 10, 2026, 10:30 PM CET / 04:30 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON DEVELOPING INNOVATIVE SOLUTIONS FOR OBSTRUCTIVE SLEEP APNEA (OSA), HAS COMPLETED A $95 MILLION EQUITY FINANCING AND ANTICIPATES RECEIPT OF THE $15 MILLION SECOND TRANCHE OF ITS EUROPEAN INVESTMENT BANK LOAN, WHICH REPRESENTS AN AGGREGATE OF $110 MILLION IN NEW CAPITAL. THIS MILESTONE MARKS A TURNING POINT FOR NYXOAH AS THE COMPANY ENTERS ITS NEXT PHASE OF U.S.-DRIVEN GROWTH AND LONG-TERM VALUE CREATION.

$110 MILLION IN AGGREGATE FINANCINGS TO ACCELERATE GENIO'S U.S. COMMERCIAL LAUNCH

REGULATED INFORMATION NYXOAH ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING MONT-SAINT-GUIBERT, BELGIUM  JUNE 10, 2026, 10:05 PM CET / 4:05 PM ET  NYXOAH SA (EURONEXT BRUSSELS/ NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON DEVELOPING INNOVATIVE SOLUTIONS FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING IN THE UNITED STATES, WHICH INCLUDED SHARES SOLD IN A PRIVATE OFFERING TO CERTAIN QUALIFIED OR INSTITUTIONAL INVESTORS OUTSIDE THE UNITED STATES, INCLUDING WITHIN THE EUROPEAN UNION, OF 55,232,558 ORDINARY SHARES AT AN OFFERING PRICE OF $1.72 (EUR 1.48) PER SHARE, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE TOTAL GROSS PROCEEDS FROM THE PUBLIC OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY NYXOAH, IS APPROXIMATELY $95.0 MILLION (APPROXIMATELY EUR 81.9 MILLION).

NYXOAH ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING

INSIDE INFORMATION REGULATED INFORMATION NYXOAH ANNOUNCES PRICING OF $95 MILLION UNDERWRITTEN PUBLIC OFFERING MONT-SAINT-GUIBERT, BELGIUM  JUNE 5, 2026, 5:25 PM CET / 11:25 AM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON DEVELOPING INNOVATIVE SOLUTIONS FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING IN THE UNITED STATES, WHICH INCLUDES SHARES SOLD IN A PRIVATE OFFERING TO CERTAIN QUALIFIED OR INSTITUTIONAL INVESTORS OUTSIDE THE UNITED STATES, INCLUDING WITHIN THE EUROPEAN UNION, OF 55,232,558 OF ITS ORDINARY SHARES AT AN OFFERING PRICE OF $1.72 (EUR 1.48) PER SHARE, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE ORDINARY SHARES ARE BEING OFFERED BY NYXOAH AND THERE ARE NO SELLING SHAREHOLDERS PARTICIPATING IN THE OFFERING.

NYXOAH ANNOUNCES PRICING OF $95 MILLION UNDERWRITTEN PUBLIC OFFERING

INSIDE INFORMATION REGULATED INFORMATION NYXOAH ANNOUNCES PROPOSED OFFERING OF ORDINARY SHARES MONT-SAINT-GUIBERT, BELGIUM  JUNE 4, 2026, 10:02 PM CET / 4:02 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON DEVELOPING INNOVATIVE SOLUTIONS FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THE COMMENCEMENT OF A PROPOSED UNDERWRITTEN PUBLIC OFFERING IN THE UNITED STATES, WHICH MAY INCLUDE SHARES SOLD IN A PRIVATE OFFERING TO CERTAIN QUALIFIED OR INSTITUTIONAL INVESTORS OUTSIDE THE UNITED STATES, INCLUDING WITHIN THE EUROPEAN UNION. ALL OF THE ORDINARY SHARES ARE BEING OFFERED BY NYXOAH AND THERE ARE NO SELLING SHAREHOLDERS PARTICIPATING IN THE PROPOSED OFFERING.

NYXOAH ANNOUNCES PROPOSED OFFERING OF ORDINARY SHARES

INSIDE INFORMATION REGULATED INFORMATION NYXOAH ENTERS NEW CHAPTER OF LONG TERM VALUE CREATION COMMENCEMENT OF PROCESS TO TRANSITION TO A U.S.-BASED CEO TRANSITION TO SUPPORT FURTHER ACCELERATION OF COMMERCIAL GENIO LAUNCH IN THE UNITED STATES MONT-SAINT-GUIBERT, BELGIUM  JUNE 4, 2026, 10:01 PM CET / 4:01 PM ET  NYXOAH SA (EURONEXT BRUSSELS/NASDAQ: NYXH) (NYXOAH OR THE COMPANY), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON DEVELOPING INNOVATIVE SOLUTIONS FOR OBSTRUCTIVE SLEEP APNEA (OSA), TODAY ANNOUNCED THE COMMENCEMENT OF A LEADERSHIP TRANSITION PROCESS IN ORDER TO FURTHER ACCELERATE THE COMPANY'S U.S. COMMERCIAL TRACTION. FOLLOWING SEVEN SUCCESSFUL YEARS LEADING NYXOAH, OLIVIER TAELMAN, TOGETHER WITH THE BOARD OF DIRECTORS, HAS DECIDED THAT THIS IS THE RIGHT MOMENT TO TRANSITION LEADERSHIP TO A U.S.-BASED CHIEF EXECUTIVE OFFICER AS THE COMPANY ENTERS ITS NEXT PHASE OF U.S.-DRIVEN GROWTH AND VALUE CREATION.

Nyxoah S.A.

NYXH

Price

Financial Reports

No items found.

Press Releases

Nyxoah S.A.

NYXH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NYXH